Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis

NCT06880276 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

360

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: 1.5% QLM3003 ointment
DRUG: 2% QLM3003 ointment
DRUG: QLM3003 Placebo

Sponsor

Qilu Pharmaceutical Co., Ltd.